

Title (en)  
METHODS AND COMPOSITIONS FOR USING SURAMIN, PENTOSAN POLYSULFATE, TELOMERASE ANTISENSE, AND TELOMERASE INHIBITORS

Title (de)  
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERWENDUNG VON SURAMIN, PENTOSANPOLYSULFAT, TELOMERASE-ANTISENSE UND TELOMERASE-HEMMERN

Title (fr)  
TECHNIQUES ET COMPOSITIONS D'UTILISATION DE SURAMINE, DE POLYSULFATE PENTOSANE, D'ANTISENS DE TELOMERASE ET D'INHIBITEURS DE LA TELOMERASE

Publication  
**EP 1606302 A4 20090218 (EN)**

Application  
**EP 04706977 A 20040130**

Priority

- US 2004002609 W 20040130
- US 44406103 P 20030131

Abstract (en)  
[origin: WO2004070008A2] The invention provides methods and compositions for inhibiting telomerase activity and treatment of telomerase mediated conditions or diseases. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents, surgery, or radiation in the treatment of conditions or diseases mediated by telomerase activity, such as in the treatment of cancer.

IPC 8 full level  
**A61K 31/00** (2006.01); **A61K 31/185** (2006.01); **A61K 31/737** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C07H 21/04** (2006.01); **C12N 15/11** (2006.01); **C12N 15/113** (2010.01)

IPC 8 main group level  
**C12N** (2006.01)

CPC (source: EP)  
**A61K 31/00** (2013.01); **A61K 31/185** (2013.01); **A61K 31/737** (2013.01); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C12N 15/1137** (2013.01); **C12Y 207/07049** (2013.01); **C12N 2310/11** (2013.01); **C12N 2310/111** (2013.01)

Citation (search report)

- [X] SKLAR GEOFFREY N ET AL: "Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: The role of apoptosis", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 150, no. 5, 1 January 1993 (1993-01-01), pages 1526 - 1532, XP009109244, ISSN: 0022-5347
- See references of WO 2004070008A2

Citation (examination)

- EISENBERGER MARIO A. ET AL: "Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 13, no. 9, 1 September 1995 (1995-09-01), pages 2174 - 2186, XP002332944, ISSN: 0732-183X
- LA ROCCA R.V. ET AL: "SURAMIN IN ADRENAL CANCER MODULATION OF STEROID HORMONE PRODUCTION CYTOTOXICITY IN-VITRO AND CLINICAL ANTITUMOR EFFECT", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, ENDOCRINE SOCIETY, CHEVY CHASE, MD, vol. 71, no. 2, 1 January 1990 (1990-01-01), pages 497 - 504, XP009130250, ISSN: 0021-972X
- CHIJIJOKE C.P. ET AL: "Clinical pharmacokinetics of suramin in patients with onchocerciasis", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 54, no. 3, May 1998 (1998-05-01), pages 249 - 251, ISSN: 0031-6970
- KLIJN J.G.M. ET AL: "Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 37, no. 6, 20 December 1990 (1990-12-20), pages 1089 - 1095, XP023549111, ISSN: 0960-0760, [retrieved on 19901220]

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2004070008 A2 20040819; WO 2004070008 A3 20050526; WO 2004070008 A8 20050929**; AU 2004209428 A1 20040819; CA 2515000 A1 20040819; CN 1768075 A 20060503; EP 1606302 A2 20051221; EP 1606302 A4 20090218; JP 2007525414 A 20070906

DOCDB simple family (application)  
**US 2004002609 W 20040130**; AU 2004209428 A 20040130; CA 2515000 A 20040130; CN 200480009121 A 20040130; EP 04706977 A 20040130; JP 2006503176 A 20040130